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1a,25-Dihydroxyvitamin D3 (1a,25(OH)2D3) and its
analogs are used to treat psoriasis because of their
potent antiproliferative activity. They have the
potential for causing hypercalcemia, however, and
patients often become resistant to the drug. We
examined the feasibility of enhancing the cutaneous
production of 1a,25(OH)2D3 using a human 25-
hydroxyvitamin D-1a-hydroxylase (1a-OHase) plas-
mid. The 1a-OHase gene was fused to the green
¯uorescent protein gene (1a-OHase-GFP) driven by
the cytomegalovirus promoter. Transfection of
cultured normal human keratinocytes with the 1a-
OHase-GFP plasmid resulted in a marked increase in
the expression of 1a-OHase-GFP in the mitochon-
dria. Transfection of keratinocytes with 1a-OHase-
GFP or 1a-OHase plasmids in vitro enhanced the 1a-
OHase activity substantially and increased the sensi-
tivity of the keratinocytes to the antiproliferative
effect of 25(OH)D3. The 1a-OHase-GFP plasmid
was topically applied to shaved C57/BL6 mice.
Twenty-four hours after topical application, immu-
nohistochemical analysis of the skin for 1a-OHase-
GFP revealed the presence of 1a-OHase-GFP in the
epidermis and epidermal appendages including the
hair follicles. The results from this study offer a
unique new approach for the topical treatment of
hyperproliferative disorders such as psoriasis and skin
cancer using the 1a-OHase gene that could locally
increase the production of 1a,25(OH)2D3 without
causing hypercalcemia or resistance. Key words: 1a,
25-dihydroxyvitamin D3/epidermal transfection/gene ther-
apy/green ¯uorescent protein/plasmid DNA/vitamin D.
J Invest Dermatol 116:910±914, 2001
V
itamin D is biologically inert and requires two
successive hydroxylations ®rst in the liver to form
25-hydroxyvitamin D3 (25(OH)D3) and then in the
kidney to its biologically active form 1a,25-dihy-
droxyvitamin D3 (1a,25(OH)2D3) (Holick, 1999).
Once formed, 1a,25(OH)2D3 goes to its target tissues and interacts
with a speci®c nuclear receptor, the vitamin D receptor (Stumpf et
al, 1979). 1a,25(OH)2D3 is not only important in calcium
metabolism, but also has pro-differentiation and cell growth
inhibitory activities (Tanaka et al, 1982; Hosomi et al, 1983;
Smith et al, 1986; Chen et al, 1993). The enzyme 25-
hydroxyvitamin D-1a-hydroxylase (1a-OHase) that is responsible
for producing 1a,25(OH)2D3 is a cytochrome P450 enzyme that is
present in the mitochondria. This enzyme is not only present in the
kidney, but is found in many other tissues including activated
macrophage, prostate, and skin (Bikle et al, 1986; Adams et al, 1990;
Schwartz et al, 1998).
The cDNAs encoding the mouse, rat, and human 1a-OHase
have been cloned (Fu et al, 1997; Takeyama et al, 1997; Kitanaka et
al, 1998; Kong et al, 1999). The human renal and nonrenal 1a-
OHase cDNA sequences are 100% identical. The presence of 1a-
OHase in keratinocytes suggests an autocrine/paracrine role for
1a,25(OH)2D3 that may be responsible for locally modulating cell
proliferation and differentiation. The potent antiproliferative and
pro-differentiating effects of 1a,25(OH)2D3 and its analogs on
keratinocytes has led to the development of these compounds as
new therapies for the hyperproliferative skin disease psoriasis
(Morimoto et al, 1986; Kragballe et al, 1988; Smith et al, 1988; Van
De Kerkhof et al, 1989; Perez et al, 1996). Topically applied active
vitamin D drugs, however, can be absorbed through the skin to
cause hypercalcemia (Bower et al, 1991; Hoech et al, 1994).
Furthermore only 40%±60% of patients have a good response to
this therapy and a resistance to the therapy may be developed after
months of use. Therefore there is a need for an alternative strategy
to increase the local production of 1a,25(OH)2D3 in hyperproli-
ferative cells.
During the past decade, advances in the introduction of genes to
tissues and organs have greatly enhanced the prospect of gene
therapy for humans (Katz, 1999). The topical application of the 1a-
OHase gene to the skin to increase local 1a-OHase activity may
provide a unique and effective therapeutic approach for hyperpro-
liferative disorders of the skin such as psoriasis. We report on the
feasibility of introducing the 1a-OHase gene into cultured normal
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human keratinocytes, which increased the 1a-OHase activity and
sensitivity to the antiproliferative activity of 25(OH)D3 in vitro. We
also show that the topical application of the 1a-OHase cDNA
plasmid on mice enhanced the cutaneous expression of the 1a-
OHase in vivo.
MATERIALS AND METHODS
Plasmid construction Polymerase chain reaction (PCR) mutagenesis
was used to generate the 1a-OHase±green ¯uorescent protein (1a-
OHase-GFP) fusion construct from 1a-OHase cDNA (Kong et al,
1999). The forward oligonucleotide primer (5¢-GCA CGA ATT CAA
TGA CCC AGA C-3¢) was designed to introduce an EcoRI
endonuclease site 10 base pairs upstream of the 1a-OHase start codon.
The reverse oligonucleotide primer (5¢-GAC CGT AAG CTT CTA
TCT GTC-3¢) was designed to mutate the endogenous stop codon and
to introduce a Hind III endonuclease site just downstream of the stop
codon. The resulting 1a-OHase(-stop) fragment was ligated into
pCR3.1 T/A cloning vector (Invitrogen, Carlsbad, CA). Multiple
positive clones were isolated and con®rmed by restriction analysis and
nucleotide sequencing. The 1a-OHase(-stop).pCR3.1 positive clone was
ligated to pEGFP vector (Clontech, Palo Alto, CA). 1a-OHase(-
stop).pEGFP plasmid DNA was puri®ed using Qiagen Maxi Puri®cation
Kit (Qiagen, Chatsworth, CA).
Transfections Normal human keratinocytes were obtained from
neonatal foreskin as previously described (Rheinwald and Green, 1975)
and grown in serum-free de®ned medium (Chen et al, 1995).
Transfection of keratinocytes was carried out using LipofectAmine Kit
(Life Technologies, Grand Island, NY). Cells were grown to about 60%
con¯uency in the absence of antibiotics, at which time the cells were
exposed to fresh medium and added with freshly prepared 1a-OHase-
GFP cDNA-LipofectAmine Reagent complexes (0.05 ml) as described in
the protocol supplied by the company. The cells were incubated for 3 h
at 37°C with 5% CO2 and then the transfection solution was removed,
fresh medium was added, and the cells were incubated for an additional
18±48 h. Transfection ef®ciency of 1a-OHase-GFP in normal human
keratinocytes between different experiments ranged from 20% to 30%.
The expression and the appearance of 1a-OHase-GFP fusion protein
inside the transfected keratinocytes were con®rmed by detecting the
green ¯uorescence using scanning laser confocal microscopy (InSight
Plus, Meridian Instruments, Okemos, MI) at 6003.
Reverse transcription PCR The normal human keratinocyte
transfection conditions were the same as for confocal microscopy.
Twenty-four hours post-transfection, cells were washed once with 1 3
phosphate-buffered saline (PBS), trypsinized for 10 min in 1 3 trypsin
ethylenediamine tetraacetic acid (EDTA), and spun for 10 min at
5000 rpm. Total RNA isolation was performed using SV Total RNA
Isolation System (Promega, Madison, WI). Two micrograms of total
RNA isolated from treated cells were reverse transcribed into single
stranded cDNA at 37°C for 2 h using Superscript II RNase H Reverse
Transcriptase (Life Technologies, Rockville, MD). Two hundred
nanograms of single stranded cDNA template were used in each PCR.
The following sequence speci®c primers were designed: GFP sense
primer 5¢-CAA GCA GAA GAA CGG CAT CAA-3¢ and antisense
primer 5¢-GGA CTG GGT GCT CAG GTA GTG-3¢; 1a-OHase-GFP
sense primer 5¢-GAG GTG CAG CCT GAG CCA-3¢ and antisense
primer 5¢-CCA GCT CGA CCA GGA GGT-3¢. The PCR protocol
was as follows: 95°C for 10 min and then for 40 cycles, denaturation at
95°C for 15 s, and anneal/extend at 60°C for 1 min. One-®fth of the
product was analyzed on a 4% agarose gel.
Western blot analysis Twenty-four hours post-transfection, cell
lysates from normal human keratinocytes transfected with either GFP
alone or 1a-OHase-GFP were prepared as follows: cells were washed
once with ice-cold PBS, scraped with a rubber policeman in ice-cold
RIPA buffer [1% Nonidet P-40, 1% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS), 150 mM NaCl, 5 mM EDTA, and 10 mM
sodium phosphate, pH 7.2, with complete protease inhibitor mixture],
and sonicated at a concentration of 1 3 106 cells per 100 ml.
Approximately 10 mg of protein in total lysate were loaded per lane on
an 8% SDS polyacrylamide gel. The gel was electrophoresed and
transferred onto a nitrocellulose membrane. The membrane was then
rinsed brie¯y with 5% milk-TBST blocking buffer (25 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 0.05% Tween-20) for 30 min with gentle
shaking. The membrane was further incubated with anti-GFP antibody
(Clontech) in 0.5% milk-TBST for 1 h with gentle shaking. It was then
washed three times for 10 min each with 0.5% milk-TBST followed by
an antirabbit peroxidase conjugate for 30 min in 0.5% milk-TBST. It
was washed twice for 10 min each in TBST and twice for 10 min each
in TBS and chemiluminescent substrate luminal/iodophenol (New
England Nuclear, Boston, MA) was added as per the manufacturer's
instruction. The membrane was exposed to X-ray ®lm for 3 s to 5 min.
1a-OHase enzyme activity The 1a-OHase enzyme activity was
determined 24 h after transfection in the presence of 0.1 mCi of 3H-
25(OH)D3 (New England Nuclear) and 10 mM 1,2-dianilinoethane by
high performance liquid chromatography using methylene
chloride:isopropanol (19:1) as the mobile phase as described previously
(Schwartz et al, 1998). The retention volumes for 3H-25(OH)D3 and
3H-1a,25(OH)2D3 were con®rmed with standard nonradioactive
25(OH)D3 and 1a,25(OH)2D3. The enzyme activity was expressed as
pmol of 1a,25(OH)2D3 per mg protein per h.
Proliferation assay The antiproliferative effects of 25(OH)D3 on
transfected normal human cultured keratinocytes were investigated in 24-
Figure 1. Cellular distribution of 1a-OHase-
GFP fusion protein in the mitochondria of
1a-OHase-GFP cDNA transfected normal
human keratinocytes. Cells were transfected
with either the 1a-OHase-GFP plasmid (a±c) or
GFP plasmid (d); 24 h later the cells transfected
with 1a-OHase-GFP were treated with
MitoTracker (Molecular Probes, Eugene, OR)
(10 nM) for 15 min and observed live using
scanning laser confocal microscopy (6003). (a)
The appearance of 1a-OHase-GFP green
¯uorescence using a ¯uorescein ®lter. (b) The
image of the same cell shown in (a) stained with
the mitochondrial speci®c red ¯uorescent
indicator MitoTracker using a rhodamine ®lter. (c)
The superimposed images from (a) and (b)
denoting the yellow-green ¯uorescence where the
1a-OHase-GFP is superimposed on the
mitochondrial ¯uorescence. (d) Appearance of the
GFP green ¯uorescence using a ¯uorescein ®lter.
Scale bar: 50 mm.
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well plates by determining 3H-thymidine incorporation. Twenty-four
hours after transfection, keratinocytes were treated with 25(OH)D3
(10±9, 10±8, 10±7 M) for 18 h. Forty-two hours after transfection, the
dosing medium was replaced with 0.5 ml of fresh basal medium
containing [methyl-3H]thymidine (New England Nuclear) and 3H-
thymidine incorporation into DNA was performed as described
previously (Smith et al, 1986). The results were expressed as percentage
of radioactivity incorporated in the absence of 25(OH)D3.
Topical application of 1a-OHase-GFP plasmid and
immunohistochemistry Eight-week-old C57/BL6 female mice in
telogen phase were depilated with a wax/rosin mixture on their dorsal
surface as described previously (Schilli et al, 1997). Depilation was
followed by tape-stripping the stratum corneum twice with Hair
Remover Wax Strip Kit (Del Laboratories, Farmingdale, NY). The skin
surface was then cleaned with ethanol and allowed to cool for 15 min.
Twenty microliters of a 1 mg per ml solution of naked plasmid DNA of
1a-OHase-GFP plasmid, or water alone, were applied to a 1 cm2 area of
the pretreated skin as previously described (Fan et al, 1999; Yu et al,
1999). Twenty-four hours after topically applying naked cDNA to
abraded mouse skin, biopsies were taken, embedded in Tissue-Tek OCT
compound (Sakura Finetek, Torrance, CA), and ¯ash frozen, and 5 mm
sections were taken. Sections were ®xed in 100% acetone and blocked
with 4% fatty acid free bovine serum albumin (BSA)/0.1% Triton X-100
in PBS for 1 h at room temperature. The sections were then incubated
with 40 mg per ml of rabbit anti-GFP antibody (Clontech) in 4% BSA±
PBS solution overnight at 4°C. Following three washes in PBS for
5 min the next day, the sections were incubated with goat antirabbit-
biotin label antibody (Vector, Burlingame, CA) at the appropriate
dilution for 2 h at room temperature. The sections were washed three
times with PBS and incubated with a streptavidin-alkaline phosphatase
conjugated antibody (Vector) for 1 h at room temperature at the
appropriate dilution. Fluorescence was developed using Phosphatase
Substrate kit I (Vector) for approximately 10 min. Sections were then
rinsed in distilled water, mounted with Permount (Fisher, Pittsburgh,
PA), and examined for ¯uorescence using a Nikon ¯uorescence
microscope (Melville, NY) with a rhodamine ®lter system and standard
compound light microscope at 2003.
RESULTS
Normal human keratinocytes transfected with 1a-OHase-
GFP cDNA plasmid express the enzyme in
mitochondria. The expression vector encoding the 1a-
OHase-GFP fusion protein driven by the cytomegalovirus
promoter was transfected into normal human cultured
keratinocytes to examine the expression and the appearance of
the cellular distribution of the 1a-OHase-GFP fusion protein using
scanning laser confocal microscopy. The ¯uorescence of the 1a-
OHase-GFP protein in live transfected keratinocytes showed an
organelle distribution that was consistent with the expected
location for the cytochrome P450-1a-OHase (Fig 1a) (Jones,
1999). The same live transfected keratinocytes were also stained
with a mitochondrial speci®c dye (Fig 1b). When both images
were superimposed the resulting image showed colocalization of
the 1a-OHase-GFP green ¯uorescence with the mitochondrial red
¯uorescence that appears yellowish-green, con®rming that the 1a-
OHase-GFP protein was expressed in the mitochondria (Fig 1c).
This is in contrast to a live keratinocyte that was transfected with
the control GFP plasmid. There was uniform ¯uorescence
throughout the cytoplasm, which is consistent with the GFP
protein being expressed in the cytoplasm (Fig 1d). To con®rm the
expression of the 1a-OHase-GFP, we examined the protein from
transfected normal human keratinocytes. Normal human
keratinocytes transfected with 1a-OHase-GFP cDNA plasmid
produced the appropriate 84 kDa size fusion protein on Western
blot analysis (Fig 2a); this was not observed in normal human
keratinocytes transfected with GFP cDNA plasmid alone.
Furthermore, the appropriate 26.3 kDa size GFP product was
observed only in normal human keratinocytes transfected with GFP
cDNA plasmid and not in normal human keratinocytes transfected
with 1a-OHase-GFP cDNA plasmid (Fig 2b). We examined the
1a-OHase-GFP mRNA expression of the normal human
keratinocytes transfected with 1a-OHase-GFP cDNA plasmid.
By using sequence speci®c primers for reverse transcriptase PCR to
amplify an amplicon that spanned the 1a-OHase-GFP junction,
only one PCR product of 175 bp was observed in normal human
keratinocytes transfected with 1a-OHase-GFP cDNA plasmid and
it was not observed in normal human keratinocytes transfected with
GFP cDNA plasmid alone (Fig 2c). Sequence speci®c primers to
GFP alone, however, produced PCR products of 150 bp that were
observed in normal human keratinocytes transfected with both
GFP cDNA plasmid and 1a-OHase-GFP cDNA plasmid (Fig 2d).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) speci®c
primers were also used to con®rm equivalent amounts of cDNA
(Fig 2e). No PCR products were observed in PCRs containing
total RNA of each sample or primers alone, assuring that there was
no plasmid or genomic contamination (data not shown).
Increased conversion of 25(OH)D3 to 1a,25(OH)2D3 by
normal human keratinocytes transfected with 1a-OHase-
GFP To determine whether the expressed 1a-OHase-GFP was
functional, we examined the ef®ciency in the conversion of 3H-
25(OH)D3 to
3H-1a,25(OH)2D3 in keratinocytes transfected with
1a-OHase-GFP. A representative elusion pro®le from high
performance liquid chromatography analysis shows an increased
conversion of 3H-25(OH)D3 to
3H-1a,25(OH)2D3 in transfected
normal human keratinocytes with 1a-OHase-GFP plasmid
(Fig 3b) compared with the endogenous level in the GFP
transfected control (Fig 3a). High performance liquid
chromatography analysis revealed an 85% 6 4.7% (mean 6 SEM;
n = 6) increase in the conversion of 3H-25(OH)D3 to
3H-
1a,25(OH)2D3 in keratinocytes transfected with 1a-OHase-GFP
above basal activity (transfected with GFP vector alone; n = 3)
(Fig 3c). The 1a-OHase gene alone without the GFP tag was also
transfected into keratinocytes. These cells showed a 111% 6 5.7%
(mean 6 SEM; n = 3) increase in the conversion of 3H-25(OH)D3
Figure 2. The expression of GFP and 1a-OHase-GFP protein
and mRNA in normal human keratinocytes transfected with GFP
or 1a-OHase-GFP cDNA plasmid. Protein and mRNA expression
was observed 24 h after transfection. (a, b) Western blot analysis of
lysates from normal human keratinocytes transfected with either GFP (left
lane) or 1a-OHase-GFP (right lane) cDNA plasmid. (c±e) Reverse
transcriptase PCR products of RNA isolated from normal human
keratinocytes transfected with either GFP (left lane) or 1a-OHase-GFP
(right lane) cDNA plasmid using sequence speci®c primers spanning the
1a-OHase-GFP fusion junction (c), sequence speci®c primers to the
GFP epitope tag (d), or sequence speci®c primers to GAPDH (e).
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to 3H-1a,25(OH)2D3. This was not statistically signi®cantly
different from the 1a-OHase-GFP transfected cells demonstrating
that the 26.3 kDa GFP tag did not signi®cantly alter the function of
1a-OHase. There was no difference in 1a-OHase activity in cells
transfected with either GFP cDNA plasmid, PCR 3.1 vector
plasmid, or LipofectAmine alone (data not shown).
Enhanced antiproliferative activity of 25(OH)D3 in
keratinocytes transfected with the 1a-OHase cDNA
plasmid Once we established that keratinocytes transfected
with 1a-OHase and 1a-OHase-GFP had enhanced 1a-OHase
activity, we evaluated whether the enhanced conversion of
25(OH)D3 to 1a,25(OH)2D3 would result in an increased
sensitivity to the antiproliferative effects of 25(OH)D3. The
antiproliferative activity of 25(OH)D3 was determined in the
transfected keratinocytes using the 3H-thymidine incorporation
assay (Smith et al, 1986; Chen et al, 1995). In Fig 4, keratinocytes
transfected with 1a-OHase showed signi®cant decreases in 3H-
thymidine incorporation of 25 6 5.0%, 26 6 3.4%, and
54 6 0.9% at 10±9 M, 10±8 M, and 10±7 M of 25(OH)D3 (mean
6 SEM; n = 8±24), respectively, compared to their respective
liposome or vector alone control. There was no signi®cant
difference in 25(OH)D3 responses in cells transfected with either
LipofectAmine or vector alone (Fig 4).
Figure 5. Immunohistochemical staining for
the 1a-OHase-GFP protein in epidermal
transfected mouse skin with the 1a-OHase-
GFP plasmid shows marked epidermal and
hair follicle expression. Water alone (a, c) or
1a-OHase-GFP plasmid in water (b, d) was
applied topically to depilated, taped, abraded skin
and the skin was examined 24 h later by using
either ¯uorescence microscopy (a, b) or light
microscopy (c, d) (2003). The red ¯uorescence or
red-brown staining that only appears in (b) or (d)
indicates the presence of 1a-OHase-GFP fusion
protein in the skin transfected with 1a-OHase-
GFP plasmid. Scale bar: 100 mm.
Figure 3. Effects of GFP vector, 1a-OHase cDNA, or 1a-OHase-
GFP cDNA transfection on the conversion of 25(OH)D3 to
1a,25(OH)2D3 in normal human keratinocytes. 1a-OHase enzyme
activity was determined 24 h after transfection by the conversion of
3H-25(OH)D3 to
3H-1a,25(OH)2D3 as described in Materials and
Methods. (a, b) Representative normal phase high performance liquid
chromatography elusion pro®le of methanol cell extracts from normal
human keratinocytes transfected with either GFP plasmid (a) or 1a-
OHase-GFP plasmid (b). (c) Enhanced 1a-OHase enzyme activity in
normal human keratinocytes transfected with either 1a-OHase-GFP or
1a-OHase plasmid over cells transfected with vector (control) or with
GFP alone. Each value of 1a-OHase activity expressed as the percentage
of conversion is the mean 6 SEM of three to six determinations.
*p < 0.005, **p < 0.001 compared to the controls by unpaired Student t
test.
Figure 4. Antiproliferative effects of 1a-OHase in transfected
normal human keratinocytes shows an increased inhibition of cell
growth. Effect of 25(OH)D3 on
3H-thymidine incorporation into DNA
in normal human keratinocytes transfected with sense and antisense 1a-
OHase-GFP cDNA. The antiproliferative activity of 25(OH)D3 was
determined by 3H-thymidine incorporation into DNA in keratinocytes
transfected with liposome (solid bars), in keratinocytes transfected with
vector alone (white bars), and in keratinocytes transfected with 1a-OHase
for 45 h (dark gray bars) as described in Materials and Methods. Twenty-
four hours after transfection, cells were treated with 25(OH)D3 (10
±9,
10±8, 10±7 M) for 18 h and then incubated with 3H-thymidine for 3 h.
Each value is the mean 6 SEM of eight to 24 determinations. *p < 0.03
compared to LipofectAmine or vector alone controls by unpaired
Student t test.
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1a-OHase-GFP is expressed in vivo in the skin of C57/BL6
mice that received the 1a-OHase-GFP plasmid
topically Naked 1a-OHase-GFP plasmid DNA in water was
topically applied to mouse skin to see whether the gene could be
expressed in vivo in the epidermis. The expression of the 1a-
OHase-GFP protein was detected with a GFP antibody. No cross-
reactivity of the GFP antibody was detected in either the epidermis
or dermis of the skin treated with water vehicle (Fig 5a). As
indicated in Fig 5(b) by the red ¯uorescence of the ¯uorophore
secondary antibody (Vector Bioscience, Eugene, OR), however,
there was marked expression of the 1a-OHase-GFP in all the cells
in the epidermis of the mouse that received a single topical
application of the 1a-OHase-GFP plasmid DNA 24 h previously.
These results were con®rmed using compound light microscopy
with the 1a-OHase-GFP located in the epidermis and epidermal
appendages indicated by the red-brown staining observed in the
cross-section of skin in Fig 5(d) compared with skin from a control
mouse that was treated with water vehicle (Fig 5c).
DISCUSSION
Results from this study demonstrate the feasibility of using the 1a-
OHase plasmid for gene therapy to treat hyperproliferative
disorders of the skin such as psoriasis and skin cancer. In vitro the
increase in mitochondrial expression of 1a-OHase resulted in
increased conversion of 25(OH)D3 to 1a,25(OH)2D3. The
enhanced 1a-hydroxylase activity imparted increased sensitivity
to the antiproliferative activity of 25(OH)D3, presumably because
of the increased conversion of 25(OH)D3 to 1a,25(OH)2D3 within
the transfected keratinocytes. Thus, topically applying a plasmid
construct of the 1a-OHase gene to psoriatic lesions should result in
the local enhanced production of 1a,25(OH)2D3 in psoriatic skin
cells. The increased intracellular levels of 1a,25(OH)2D3 should in
turn restore cells to normal proliferation and differentiation,
resulting in remission in the disease similar to if the skin lesion
was treated topically with 1a,25(OH)2D3 or one of its analogs. This
may be a preferred method of treatment not only for psoriasis but
also for other hyperproliferative disorders of the skin such as actinic
keratoses and skin cancer. Increasing 1a,25(OH)2D3 locally in
psoriatic keratinocytes or cancer cells that have a vitamin D
receptor has the advantage of attaining very high intracellular
concentrations of 1a,25(OH)2D3, thereby giving the hormone the
opportunity to downregulate the cells' growth for at least several
days (Smith et al, 1988; Bower et al, 1991; Hoech et al, 1994). The
localized increase in the concentration of 1a,25(OH)2D3 within
the hyperproliferative cells is not likely to have any systemic effects
such as hypercalcemia. The proliferative cells may also be less prone
to developing a resistance to the therapeutic effectiveness of
1a,25(OH)2D3 if it is produced in sustained higher levels inside the
cell.
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